GRI Bio Inc
GRI
GRI Bio Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue pre-clinical biotech burning 9.2M TTM cash with only 4.1M remaining - ~5 months runway at current rate[Cash and Equivalents]
- Negative enterprise value (-3.1M) as cash exceeds tiny 0.9M market cap - trading below liquidation value[Enterprise Value]
- R&D of 6.1M TTM is 54% of total opex - focused spend but insufficient scale for meaningful clinical progress[Research and Development]
Watch Triggers
- Cash and Equivalents: Falls below 2M or financing announced — Signals imminent dilution event or potential bankruptcy risk
- Shares Outstanding: Increases >50% from 2.6M — Quantifies dilution impact on per-share value
- Research and Development: Quarterly spend drops below 1M — Would indicate wind-down of operations vs continued development
Bull Case
Negative EV (-3.1M) means market assigns zero value to pipeline - any clinical success creates asymmetric upside from sub-1M market cap base
Minimal debt (84K, 0.04 D/E) and clean balance sheet makes company attractive acquisition target for larger pharma seeking pipeline assets
Bear Case
5-month cash runway guarantees imminent dilution - 2.6M shares outstanding will likely multiply, crushing existing shareholders
Zero revenue with -99% EPS growth YoY signals deteriorating fundamentals; R&D spend too small for competitive clinical development
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage GRI's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Dilutive financing or strategic transaction required within 6 months to survive
- 4.1M cash vs 9.2M annual burn
- 1.6M equity issuance already in TTM
- No revenue pathway visible
Valuation Context
Caveats
Public Strategies Rankings
See how GRI Bio Inc ranks across different investment strategies.
Leverage GRI's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
GRI Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$1.03M | — | ||
$-7.12M | — | ||
0.00 | — | ||
$0 | — | ||
$-121.80 | — | ||
0% | 0.0% | — | |
0% | 0.0% | — | |
$-10.19M | — | ||
-2.4 | +144.4% | — | |
Beta 5Y (Monthly) | unknown | — |
GRI Dividend History
GRI Stock Splits
GRI SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
01/30/26 | 12/31/25 | 10-K | |
11/14/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/15/25 | 03/31/25 | 10-Q | |
03/14/25 | 12/31/24 | 10-K | |
11/14/24 | 09/30/24 | 10-Q | |
08/14/24 | 06/30/24 | 10-Q | |
05/10/24 | 03/31/24 | 10-Q | |
03/28/24 | 12/31/23 | 10-K | |
11/14/23 | 09/30/23 | 10-Q | |
08/14/23 | 06/30/23 | 10-Q | |
05/15/23 | 03/31/23 | 10-Q | |
02/24/23 | 12/31/22 | S-4/A | |
11/14/23 | 09/30/22 | 10-Q | |
08/14/23 | 06/30/22 | 10-Q | |
05/15/23 | 03/31/22 | 10-Q |